Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24603586 | 1.00 | ALDH1A1 (0.40) | ALDH1A1CYP2D6MAPK1TSHRELANE | |
| SCHEMBL22689142 | 0.90 | ALDH1A1 (0.33) | ALDH1A1CYP2D6TSHRELANELGALS8 | |
| SCHEMBL10309796 | 0.90 | ALDH1A1 (0.39) | ALDH1A1CYP2D6MAPK1TSHRELANE | |
| SCHEMBL22074006 | 0.82 | GJB2 (0.42) | ALDH1A1CYP2D6MAPK1TSHRLMNA | |
| SCHEMBL29551763 | 0.82 | CA2 (0.35) | CYP2D6TSHRCA12CA1CA2 | |
| SCHEMBL16317730 | 0.81 | CYP2D6 (0.47) | ALDH1A1CYP2D6MAPK1TSHRLMNA | |
| SCHEMBL2449623 | 0.81 | CYP2D6 (0.47) | ALDH1A1CYP2D6MAPK1TSHRLMNA | |
| SCHEMBL7516237 | 0.81 | CYP2D6 (0.47) | ALDH1A1CYP2D6MAPK1TSHRLMNA | |
| SCHEMBL22423316 | 0.80 | NT5E (0.37) | ALDH1A1CYP2D6MAPK1TSHRLMNA | |
| SCHEMBL1034819 | 0.80 | NT5E (0.37) | ALDH1A1CYP2D6MAPK1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716252-B2 | (Methylsulfonyl) ethyl benzene isoindoline derivatives and their pharmaceutical uses | CELGENE CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130116204-A1 | (METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2516395-A1 | (METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR THERAPEUTICAL USES | Celgene Corporation (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011079091-A1 | (METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR THERAPEUTICAL USES | CELGENE CORPORATION (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116204-A1 | (METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | ABCG2, TPMT, CYP2D6 | ALDH1A1 2444/4885CYP2D6 3/4885MAPK1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.